Skip to main content

Table 1 Patient demographics and baseline characteristics

From: Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children aged less than five years: results of an open-label, randomized, single-centre study

Characteristics

AL dispersible (n = 227)

DP paediatric (n = 227)

p value*

Age (months)

 29.6 (15.2)

 32.0 (14.9)

0.094

Weight (kg)

 12.2 (3.2)

 12.3 (3.2)

0.709

Temperature (°C)

 38.3 (1.0)

 38.3 (2.1)

0.949

Parasite density (/μL), mean (95% CI)†

38,202.2 (32,180.0 to 45,351.3)

38,545.7 (32,615.8 to 45,553.8)

0.941‡

Haemoglobin (g/dL)

 9.2 (1.9)

 9.4 (2.0)

0.293

White blood cells (x103/μL)

 9.9 (4.5)

 9.5 (3.8)

0.258

Platelets (x103/μL)

134.8 (66.1)

134.9 (67.1)

0.988

Red blood cells (x106/μL)

 3.7 (0.9)

 3.7 (0.8)

0.764

Neutrophils (%)

 41.0 (17.5)

 43.1 (17.8)

0.203

Lymphocytes (%)

 50.6 (17.2)

 48.4 (17.5)

0.182

Monocytes (%)

 7.4 (3.0)

 7.6 (4.9)

0.559

  1. Data are mean (±SD) unless otherwise specified. AL: Artemether-lumefantrine; DP: dihydroartemisinin-piperaquine; *p value from t-test or Mann–Whitney test; †Geometric mean with its 95% CI; ‡p value from t-test on the log parasite density.